Table 1 Characteristics of patients in the primary analysis according to chemotherapy cohort
Characteristic | Arm A (N = 71) | Arm B (N = 68) |
|---|---|---|
Age – median (range) | 64 (30–82) | 62 (29–81) |
WHO performance status, n (%) | ||
0, 1 | 66 (93.0 %) | 64 (94.1 %) |
2 | 5 (7.0 %) | 4 (5.9 %) |
Previous (neo-)adjuvant chemotherapy, n (%) | 38 (53.5 %) | 37 (54.4 %) |
Previous taxane-based chemotherapy, n (%) | 21 (29.6 %) | 20 (29.4 %) |
Estrogen-receptor status, n (%) | ||
negative | 10 (14.1 %) | 15 (22.1 %) |
positive | 61 (85.9 %) | 52 (76.5 %) |
unknown | 1 (1.5 %) | |
Progesterone-receptor status, n (%) | ||
negative | 23 (32.4 %) | 27 (39.7 %) |
positive | 48 (67.6 %) | 40 (58.8 %) |
unknown | 1 (1.5 %) | |
Disease evaluation, n (%) | ||
Evaluable | 13 (18.3 %) | 8 (11.8 %) |
Measurable | 58 (81.7 %) | 60 (88.2 %) |
Presence of metastases, n (%) | ||
Liver | 41 (57.7 %) | 37 (54.4 %) |
Lung | 25 (35.2 %) | 33 (48.5 %) |
Bone | 52 (73.2 %) | 49 (72.1 %) |
Brain | 0 (0 %) | 0 (0 %) |
Soft-tissue | 12 (16.9 %) | 8 (11.8 %) |
Other | 21 (29.6 %) | 13 (19.1 %) |